Percutaneous coronary intervention in perspective: drug-eluting stents as a model for regulatory review.
Kandzari
David E
DE
Division of Cardiovascular Disease, Scripps Clinic, Maildrop S1056, 10666 North Torrey Pines Rd, La Jolla, CA 92037, USA. kandzari.david@scrippshealth.org
Farb
Andrew
A
Boam
Ashley B
AB
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000331:legislation & jurisprudence*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000628:therapy*; D018795:Device Approval / Q000331:legislation & jurisprudence*; D054855:Drug-Eluting Stents; D023381:Endpoint Determination; D019317:Evidence-Based Medicine; D033161:Government Regulation; D019983:Guideline Adherence; D006291:Health Policy; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D010975:Platelet Aggregation Inhibitors